key: cord-0728849-1aze7i9c
authors: Cai, Yixin; Gao, Yi; Zhang, Ni
title: Response to Letter to the Editor
date: 2020-09-24
journal: J Thorac Oncol
DOI: 10.1016/j.jtho.2020.08.014
sha: 16edde70543019bec1c67959716015c82b355c61
doc_id: 728849
cord_uid: 1aze7i9c

nan

To the Editor: We thank Dr. Seitlinger for the interest in our work and his comments. As Dr. Seitlinger mentioned in the letter, 1 the diffusing capacity for carbon monoxide is a useful parameter to evaluate the diffusing capacity of the lung. In our center, spirometry and arterial blood gas test are routinely taken before operation for each patient; unfortunately, the diffusing capacity for carbon monoxide tests are not taken. The decision for operation was made on the basis of clinical performance, results of spirometry, and arterial blood gas test. In this cohort, patient 3 had a relatively poor lung function with forced expiratory volume in 1 second of 1.39 liter and percent forced expiratory volume in 1 second of 68.5%, whereas the preoperative arterial blood test on breathing air revealed a partial pressure of oxygen equal to 93 mm Hg and partial pressure of carbon dioxide equal to 34.1 mm Hg.

We also noted that the three patients in this cohort who died had comorbidities of interstitial lung disease, chronic obstructive pulmonary disease, and coronary atherosclerosis, respectively. As we know, comorbidities could raise the incidence of severe postoperative complications, which can further increase the risk of death for patients after lobectomy. In our cohort, none of the patients had surgery-related postoperative complications. Moreover, the clinical course of these seven patients illustrated that the disease worsened immediately after onset of symptoms of coronavirus disease 2019 (COVID-19) infection, and the fatality rate was much higher than that of the general population. These findings suggested that, besides comorbidities, the stress of lung resection might be a risk factor for death among patients who contracted COVID-19 during the perioperative period.

The effects of different operation patterns, including operation approach and lymphadenectomy on COVID-19, remains to be evaluated. Surgical stress results in a reduction in the number of CD8-positive T-cells that produce interferon gamma in response to tumorassociated antigen. 2 Interferon gamma is an important cytokine involved in the antiviral immune response. Furthermore, operation induces an elevation in the number of circulating neutrophils followed by a strong elevation in the number of inflammatory monocytes. The systemic inflammatory response induced after surgical procedure promotes the emergence of tumors whose growth was otherwise restricted by a tumorspecific T-cell response. 3 We speculated that surgical stress in patients with cancer might suppress the Tcell-mediated antiviral response.

It was indeed hard to draw a full picture on the basis of such a small sample size, but these cases provided important clinicopathologic information of the specific patient population at that time. We are thankful for the comments and for pointing out further research possibilities. Large studies and further investigation are necessary to evaluate the influence of operation on the progression of COVID-19. Recent data suggest that differences in RAF activation strategies may influence therapeutic vulnerabilities. For example, a few case series revealed that a subset of class II mutations (K601E, L597S, and L597R) might respond to BRAF and MEK inhibitors. 6,7 In addition, preclinical models suggest that inhibiting the regulatory phosphatase SHP2 or blocking the upstream receptor tyrosine kinases can suppress the proliferation of tumors with class III BRAF mutations. 4,8 In their study, Negrao et al. 7 reported that the BRAF G469-mutant H1755 cell line is sensitive to treatment with trametinib plus or minus dabrafenib. The case below summarizes the clinical course of a patient with BRAF G469Amutant NSCLC who responded to combination therapy with dabrafenib and trametinib. This patient's experience confirms the clinical activity of this combination in lung cancers with BRAF G469A mutations.

In 2017, a 62-year-old woman, former smoker, presented with symptoms of hoarseness, cough, and chest pain. Diagnostic imaging revealed a left lung mass, a solitary brain metastasis, and liver metastases. Biopsy of the lung mass confirmed programmed death-ligand 1low (10%) lung adenocarcinoma. Molecular testing revealed a BRAF G469A mutation and two TP53 mutations. The patient received first-line carboplatin combined with pemetrexed with a response that lasted 5 months. At progression, she was started second-line pembrolizumab, which was discontinued several weeks later owing to pneumonitis and ongoing progression of liver lesions. She subsequently received third-line docetaxel with no response to treatment.

After 10 months from her original diagnosis, she commenced fourth-line treatment with dabrafenib 150 mg twice a day and trametinib 2 mg daily. Dabrafenib dosing was reduced to 75 mg twice a day to address side effects of nausea and vomiting. Both symptoms resolved with dose modification. Within 1 month of initiating targeted therapy, pretreatment fatigue and dyspnea had markedly improved. Restaging scans after 2 months on therapy revealed a reduction in the size of liver masses and stability of the solitary brain lesion (Fig. 1) . She responded to treatment for 6 months before subsequent scans revealed liver and brain metastasis (Fig. 1) . The patient underwent a liver biopsy on relapse while on dabrafenib/trametinib, which revealed the persistence of BRAF G469A and the original TP53 mutations without additional acquired mutations.

To determine the prevalence of BRAF G469A mutations in NSCLC, molecular testing results from 2302 consecutive patients with NSCLC whose biopsy specimens underwent molecular testing at Massachusetts General Hospital using the SNaPshot (MGH Center for Integrated Diagnostics, Boston, MA) next-generation sequencing platform were reviewed. 9 BRAF mutations were detected in 121 NSCLC specimens (5%) (Fig. 2) . A total of 38 (1.7% of NSCLC, 31% of BRAF mutations) biopsies harbored BRAF V600E. Class II and III BRAF mutations were identified in 37 (1.6% of NSCLC, 31% of BRAF mutations) and 34 (1.5% of NSCLC, 28% of BRAF mutations) specimens, respectively. A BRAF G469A mutation was detected

Coronavirus disease 2019 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan

Letter to the editor concerning the article from Cai et al. focusing on Coronavirus Disease 2019 impact on lung cancer Resection